257 related articles for article (PubMed ID: 25385558)
41. Paraneoplastic pyoderma gangrenosum in solid organ malignancy: a literature review.
Shah M; Sachdeva M; Gefri A; Jfri A
Int J Dermatol; 2020 Feb; 59(2):154-158. PubMed ID: 31512760
[TBL] [Abstract][Full Text] [Related]
42. Pyoderma gangrenosum complicating bilateral total knee arthroplasty.
Attar S; Spangehl MJ; Casey WJ; Smith AA
Orthopedics; 2010 Jun; 33(6):441. PubMed ID: 20806762
[TBL] [Abstract][Full Text] [Related]
43. Extracutaneous involvement of pyoderma gangrenosum.
Borda LJ; Wong LL; Marzano AV; Ortega-Loayza AG
Arch Dermatol Res; 2019 Aug; 311(6):425-434. PubMed ID: 30923901
[TBL] [Abstract][Full Text] [Related]
44. Pyoderma gangrenosum: a review of pathogenesis and treatment.
Ahn C; Negus D; Huang W
Expert Rev Clin Immunol; 2018 Mar; 14(3):225-233. PubMed ID: 29406827
[TBL] [Abstract][Full Text] [Related]
45. [Successful treatment of gangrenous pyoderma with methotrexate in a patient withCrohn's disease].
Duarte-Chang C; Visuetti S
Rev Gastroenterol Peru; 2019; 39(2):175-177. PubMed ID: 31333236
[TBL] [Abstract][Full Text] [Related]
46. Pediatric Pyoderma Gangrenosum: A Retrospective Review of Clinical Features, Etiologic Associations, and Treatment.
Schoch JJ; Tolkachjov SN; Cappel JA; Gibson LE; Davis DM
Pediatr Dermatol; 2017 Jan; 34(1):39-45. PubMed ID: 27699861
[TBL] [Abstract][Full Text] [Related]
47. Use of infliximab in pyoderma gangrenosum.
Hewitt D; Tait C
Australas J Dermatol; 2007 May; 48(2):95-8. PubMed ID: 17535196
[TBL] [Abstract][Full Text] [Related]
48. [Pyoderma gangrenosum associated with rheumatoid arthritis: a case report].
Beber AA; Knob CF; Shons KR; Neumaier W; da Silva JC; Monticielo OA
Rev Bras Reumatol; 2014; 54(4):322-5. PubMed ID: 25627229
[TBL] [Abstract][Full Text] [Related]
49. Asymptomatic inflammatory bowel disease presenting with mucocutaneous findings.
Galbraith SS; Drolet BA; Kugathasan S; Paller AS; Esterly NB
Pediatrics; 2005 Sep; 116(3):e439-44. PubMed ID: 16099852
[TBL] [Abstract][Full Text] [Related]
50. TRAF3IP2 gene is associated with cutaneous extraintestinal manifestations in inflammatory bowel disease.
Ciccacci C; Biancone L; Di Fusco D; Ranieri M; Condino G; Giardina E; Onali S; Lepre T; Pallone F; Novelli G; Borgiani P
J Crohns Colitis; 2013 Feb; 7(1):44-52. PubMed ID: 22445837
[TBL] [Abstract][Full Text] [Related]
51. Ulcerative Colitis Diagnosed through Evaluation of Underlying Diseases in a Pyoderma Gangrenosum Adolescent without Gastrointestinal Symptoms.
Kwon IJ; Park JW; Park S; Lim H; Yu J; Oh SH
Ann Dermatol; 2023 Nov; 35(Suppl 2):S292-S295. PubMed ID: 38061724
[TBL] [Abstract][Full Text] [Related]
52. Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients.
Weizman A; Huang B; Berel D; Targan SR; Dubinsky M; Fleshner P; Ippoliti A; Kaur M; Panikkath D; Brant S; Oikonomou I; Duerr R; Rioux J; Silverberg M; Rotter JI; Vasiliauskas E; Haritunians T; Shih D; Li D; Melmed GY; McGovern DP
Inflamm Bowel Dis; 2014 Mar; 20(3):525-33. PubMed ID: 24487271
[TBL] [Abstract][Full Text] [Related]
53. Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease.
Wang J; Prenner J; Wang W; Sakuraba A; Hyman N; Dalal S; Hurst R; Cohen RD; Umanskiy K; Shogan BD; Alpert L; Rubin DT; Colwell J; Pekow J
Aliment Pharmacol Ther; 2020 Jun; 51(12):1365-1372. PubMed ID: 32383278
[TBL] [Abstract][Full Text] [Related]
54. The prevalence of extraintestinal diseases in inflammatory bowel disease: a population-based study.
Bernstein CN; Blanchard JF; Rawsthorne P; Yu N
Am J Gastroenterol; 2001 Apr; 96(4):1116-22. PubMed ID: 11316157
[TBL] [Abstract][Full Text] [Related]
55. Pyoderma gangrenosum as initial manifestation of Graves' disease.
Livideanu C; Lipsker D; Paul C; Juillard J; Schubert B
Clin Exp Dermatol; 2006 Sep; 31(5):659-61. PubMed ID: 16780496
[TBL] [Abstract][Full Text] [Related]
56. Infliximab for treatment of pyoderma gangrenosum associated with clinically inactive Crohn's disease. A case report.
Kouklakis G; Moschos J; Leontiadis GI; Kadis S; Mpoumponaris A; Molyvas E; Minopoulos GI
Rom J Gastroenterol; 2005 Dec; 14(4):401-3. PubMed ID: 16400359
[TBL] [Abstract][Full Text] [Related]
57. Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.
Juillerat P; Christen-Zäch S; Troillet FX; Gallot-Lavallée S; Pannizzon RG; Michetti P
Dermatology; 2007; 215(3):245-51. PubMed ID: 17823524
[TBL] [Abstract][Full Text] [Related]
58. Pyoderma Gangrenosum in a Patient with Hereditary Spherocytosis.
Kwon HI; Paek JO; Kim JE; Ro YS; Ko JY
Int J Low Extrem Wounds; 2016 Mar; 15(1):92-5. PubMed ID: 26711368
[TBL] [Abstract][Full Text] [Related]
59. Management of peristomal pyoderma gangrenosum.
Kiran RP; O'Brien-Ermlich B; Achkar JP; Fazio VW; Delaney CP
Dis Colon Rectum; 2005 Jul; 48(7):1397-403. PubMed ID: 15868233
[TBL] [Abstract][Full Text] [Related]
60. [Healing of severe morbus Crohn-related pyoderma gangrenosum after colectomy].
Henneberg J; Heidenheim M; Munck LK
Ugeskr Laeger; 2021 Mar; 183(11):. PubMed ID: 33734075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
